Want to see TRAX full AI Analyst Report?

First Tracks Biotherapeutics Inc (TRAX) Price & Analysis

42 Followers

TRAX Stock Chart & Stats

45.31

-1.64(-3.49%)

Aug 06, 2026

―

Day’s Range― - ―

52-Week Range14.72 - 49.58

Previous CloseN/A

VolumeN/A

Average Volume (3M)N/A

Market Cap

$1.54B

Enterprise Value385.53M

Total Cash (Recent Filing)$286.45M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.55

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding34,892,380

10 Day Avg. VolumeN/A

30 Day Avg. VolumeN/A

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.25

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-7.32

Forecast

1Y Price Target

$48.00

Price Target Upside― Downside

Rating ConsensusStrong Buy

Number of Analyst Covering7

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage / Conservative Debt ProfileThe company's very low debt-to-equity (~0.04–0.05) materially reduces near-term refinancing and interest burdens. Over a 2–6 month horizon this conservatism supports optionality—funding R&D, partnerships, or capital raises with less immediate solvency stress versus highly levered peers.

Improving Free Cash Flow TrendReported improvement in free cash flow growth in 2025 suggests early progress on cost control or operational efficiency. If sustained, this trend can slow runway depletion, reducing near-term financing frequency and easing dilution risk across the next several months.

Material Shareholders' Equity CushionDespite declines, a $287.5M equity base still provides a meaningful capital cushion to fund development activities in the near term. This buffer gives the company time to advance programs or pursue non-dilutive partnerships before insolvency risks become acute.

Bears Say

No Commercial RevenueAbsence of any revenue across three years means the business lacks validated commercial cash generation. The firm is structurally dependent on external financing to support operations and R&D, increasing dilution and execution risk over a multi-month horizon until commercialization or sustained partner funding occurs.

Heavy And Increasing Operating Cash BurnOperating cash outflows have accelerated year-over-year, shortening runway and raising financing urgency. Persistent negative cash flow forces reliance on equity or debt raises, which can dilute shareholders or increase leverage, limiting strategic flexibility over the next several months.

Large, Worsening Net Losses Consuming CapitalNet losses widened to materially negative levels in 2025, eroding equity and leaving returns sharply negative. Continued loss-making converts to balance-sheet drain, raising the probability of additional financing and reflecting that current investment is not yet generating commercial or operational returns.

First Tracks Biotherapeutics Inc News

First Tracks Biotherapeutics price target raised to $60 from $30 at Wedbush

Wedbush raised the firm’s price target on First Tracks Biotherapeutics to $60 from $30 and keeps an Outperform...

10d ago

ARGX

FBRX

First Tracks Biotherapeutics price target raised to $55 from $30 at Wells Fargo

Wells Fargo analyst Derek Archila raised the firm’s price target on First Tracks Biotherapeutics (TRAX) to $55 from...

10d ago

FBRX

TRAX

After Forte acquisition, H.C. Wainwright says First Tracks could be target

After Argenx (ARGX) announced a deal to acquire Forte (FBRX) for a price of $77 per share, a...

11d ago

ARGX

FBRX

First Tracks Biotherapeutics price target raised to $48 from $40 at Barclays

Barclays raised the firm’s price target on First Tracks Biotherapeutics (TRAX) to $48 from $40 and keeps an...

17d ago

TRAX

First Tracks Biotherapeutics price target raised to $44 from $30 at H.C. Wainwright

H.C. Wainwright analyst Emily Bodnar raised the firm’s price target on First Tracks Biotherapeutics (TRAX) to $44 from...

29d ago

FBRX

TRAX

First Tracks Biotherapeutics: Buy Rating Reaffirmed with Unchanged $44 Price Target on ANB033 CD122-Targeting Upside and Acquisition Potential

Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on First Tracks Biotherapeutics Inc, retaining the price...

11d ago

TRAX

Buy Rating on First Tracks (TRAX) Driven by Strengthening IL-15/CD122 Pathway Validation and Upcoming ANB033 Clinical Catalysts in Celiac Disease and Vitiligo

In a report released yesterday, Emily Bodnar from H.C. Wainwright maintained a Buy rating on First Tracks Biotherapeutics...

1M ago

TRAX

First Tracks Biotherapeutics initiated with an Overweight at Wells Fargo

Wells Fargo analyst Derek Archila initiated coverage of First Tracks Biotherapeutics (TRAX) with an Overweight rating and $30...

2M ago

TRAX

Emily Bodnar Reiterates Buy on AnaptysBio, Keeps $30 Price Target on ANB033 Progress and Solid Cash Runway

Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on First Tracks Biotherapeutics Inc, retaining the price...

3M ago

TRAX

Two new option listings and one option delisting on May 11th

New option listings for May 11th include Boost Run Inc. (BRUN) and First Tracks Biotherapeutics Inc (TRAX). Option...

3M ago

TRAX

WLAC

First Tracks Biotherapeutics files to sell 10.5M shares of common for holders

16:38 EDT First Tracks Biotherapeutics (TRAX) files to sell 10.5M shares of common for holders Published first on...

3M ago

TRAX

AnaptysBio price target lowered to $93 from $95 at Piper Sandler

Piper Sandler lowered the firm’s price target on AnaptysBio (ANAB) to $93 from $95 and keeps an Overweight...

3M ago

GSK

ANAB

First Tracks Biotherapeutics initiated with an Overweight at Piper Sandler

Piper Sandler analyst Yasmeen Rahimi initiated coverage of First Tracks Biotherapeutics (TRAX) with an Overweight rating and $54...

3M ago

TRAX

TRAX: Event-Driven Immunology Catalyst Play With Differentiated Pipeline and Valuation Upside Supporting Buy Rating

David Risinger, an analyst from Leerink Partners, has initiated a new Buy rating on First Tracks Biotherapeutics Inc...

4M ago

TRAX

TRAX FAQ

What was First Tracks Biotherapeutics Inc’s price range in the past 12 months?

First Tracks Biotherapeutics Inc lowest stock price was 14.72 and its highest was 49.58 in the past 12 months.

What is First Tracks Biotherapeutics Inc’s market cap?

First Tracks Biotherapeutics Inc’s market cap is $1.54B.

When is First Tracks Biotherapeutics Inc’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were First Tracks Biotherapeutics Inc’s earnings last quarter?

Currently, no data Available

Is First Tracks Biotherapeutics Inc overvalued?

According to Wall Street analysts First Tracks Biotherapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does First Tracks Biotherapeutics Inc pay dividends?

First Tracks Biotherapeutics Inc does not currently pay dividends.

What is First Tracks Biotherapeutics Inc’s EPS estimate?

First Tracks Biotherapeutics Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does First Tracks Biotherapeutics Inc have?

First Tracks Biotherapeutics Inc has 34,892,380 shares outstanding.

What happened to First Tracks Biotherapeutics Inc’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of First Tracks Biotherapeutics Inc?

Currently, no hedge funds are holding shares in TRAX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

First Tracks Biotherapeutics Inc Stock Smart Score

Neutral

Company Description

First Tracks Biotherapeutics Inc

First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments. The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflammatory disorders, currently advancing programs like rosnilimab, ANB033, and ANB101 through their clinical stages.

First Tracks Biotherapeutics Inc (TRAX) Earnings & Revenues

Historic Earnings Reports

TRAX Stock 12 Month Forecast

Average Price Target

$48.00

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"17":"17","28":"28","39":"39","50":"50","61":"61"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":48,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">48.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">30.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[17,28,39,50,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,44.04,45.26769230769231,46.495384615384616,47.723076923076924,48.95076923076923,50.17846153846154,51.40615384615385,52.63384615384615,53.86153846153846,55.08923076923077,56.316923076923075,57.54461538461538,58.77230769230769,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,44.04,44.34461538461538,44.64923076923077,44.95384615384615,45.25846153846154,45.56307692307692,45.86769230769231,46.17230769230769,46.47692307692308,46.78153846153846,47.08615384615385,47.39076923076923,47.69538461538461,{"y":48,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,44.04,42.96,41.88,40.8,39.72,38.64,37.56,36.480000000000004,35.4,34.32,33.24,32.16,31.080000000000002,{"y":30,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":19,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.38,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.09,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.59,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.04,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >

Similar Stocks

XNCR

Xencor

―

CTMX

CytomX Therapeutics

―

KURA

Kura Oncology

―

REPL